PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

As described by the company, sepiapterin is a natural precursor of the enzymatic co-factor BH4 -- a critical co-factor for ...

US FDA approves PTC Therapeutics’ Sephience to treat children and adults living with phenylketonuria: Warren, New Jersey Wednesday, July 30, 2025, 15:00 Hrs [IST] PTC Therapeuti ...

Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, ...

Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, July 28 th at 5:00 pm ET - WARREN, N.